Ralliant (NYSE:RAL) SVP Karen Bick Sells 5,485 Shares of Stock

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 5,485 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the completion of the transaction, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. This trade represents a 10.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ralliant Trading Down 3.8%

RAL traded down $1.78 during trading on Friday, reaching $44.58. 412,194 shares of the company’s stock were exchanged, compared to its average volume of 2,013,466. The stock has a market capitalization of $4.98 billion and a PE ratio of 22.74. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The firm has a fifty day moving average price of $49.08 and a two-hundred day moving average price of $46.63. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to the consensus estimate of $543.04 million. The company’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio is currently 10.20%.

Institutional Trading of Ralliant

Hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP raised its holdings in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. Rothschild Investment LLC grew its position in Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after buying an additional 303 shares during the period. Keybank National Association OH raised its position in Ralliant by 1.6% in the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after acquiring an additional 305 shares during the period. UMB Bank n.a. increased its holdings in shares of Ralliant by 49.6% in the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after buying an additional 326 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its position in shares of Ralliant by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after buying an additional 329 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Citigroup cut their target price on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Barclays decreased their price target on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Weiss Ratings lowered Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Zacks Research lowered Ralliant from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Ralliant presently has a consensus rating of “Hold” and a consensus price target of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.